Identification of Specific Joint-Inflammatogenic Cell-Free DNA Molecules From Synovial Fluids of Patients With Rheumatoid Arthritis

Cong Dong, Yu Liu, Chengxin Sun, Huiyi Liang, Lie Dai, Jun Shen, Wei Song, Shixin Guo, Kam W. Leong, Yongming Chen, Lai Wei, Lixin LiuFrontiers in Immunology 2020 · DOI

Abstract

Elevated cell-free DNA (cfDNA) levels in the plasma and synovial fluid of rheumatoid arthritis (RA) patients are proposed to be pathologically relevant. However, direct evidence to support this perception is lacking, and molecular feature of the cfDNA molecules with assumed pathological function is not well characterized. Here, we confirm remarkably increased levels of total synovial fluid and plasma cfDNAs in a large cohort of patients with rheumatoid arthritis compared to the counterparts in osteoarthritis, and demonstrate the potent inflammatogenic effects of RA synovial fluid cfDNA on both human monocyte cell line and primary cells related to RA. Massively parallel sequencing identifies distinct molecular pattern of cfDNA in RA, as characterized by enriching CpG-motif containing sequences. Importantly, these identified CpG-motif-rich sequences are hypomethylated in RA patients and induce severe inflammatory responses both in vitro and in vivo. Our data demonstrate the pathological role of global and specific cfDNA molecules in RA, thereby identifying novel therapeutic target candidate and potential biomarker for RA.

Introduction

Rheumatoid Arthritis (RA) is a chronic inflammatory disease characterized by joint destruction. While elevated levels of cell-free DNA (cfDNA) in the blood and synovial fluid of RA patients have been observed for years, its role remained ambiguous. Researchers sought to determine if this DNA was merely a byproduct of cellular death or an active driver of the inflammatory process. This study investigates the molecular characteristics of RA-derived cfDNA and its potential to induce arthritic symptoms.

Methodology

The study utilized a multi-faceted approach:

  • Clinical Cohort: Analysis of samples from 163 individuals (80 RA, 33 OA, 50 healthy donors).
  • Sequencing & Bioinformatics: Massively parallel whole-genome sequencing to identify 71 specific CpG-motif-rich (CMR) sequences.
  • Functional Assays: Testing the inflammatogenic potential of these sequences on human monocyte lines (THP-1) and primary synovial cells.
  • In Vivo Validation: Injecting RA-specific CMR sequences into mouse knee joints to observe arthritis induction via Micro-CT and MRI.
  • Pathway Silencing: Using siRNA to target TLR-9 to confirm the signaling pathway.

Results

Elevated cfDNA Concentrations

The study confirmed that RA patients exhibit significantly higher concentrations of cfDNA in both plasma and synovial fluid compared to healthy donors (HD) and osteoarthritis (OA) patients. Notably, the concentration in the synovial fluid was approximately 77 times higher than in the plasma, suggesting a localized inflammatory driver within the joint.

Comparison of cfDNA concentrations in plasma (A) and synovial fluid (B) showing significantly higher levels in RA patients compared to controls.

Pro-inflammatory Potential

Functional tests demonstrated that RA synovial fluid cfDNA (SFcfDNA) is highly inflammatogenic. It induced significant production of pro-inflammatory cytokines such as TNF-α in primary synovial immune cells, mimicking the effects of known inflammatory stimulants like CpG2006.

Percentage of TNF-α expressing cells in synovial fluid mononuclear cells (SFMIC) after stimulation with control, CpG2006, or RA synovial fluid cfDNA.

Discussion: The Role of Hypomethylation and TLR-9

A key finding was that RA cfDNA is enriched with CpG motifs that are hypomethylated. In healthy individuals, these motifs are typically methylated to prevent immune recognition. In RA, this hypomethylation causes the body's own DNA to mimic bacterial DNA, triggering the Toll-like Receptor 9 (TLR-9) pathway. Silencing TLR-9 effectively abolished the inflammatory response, confirming it as the primary sensor for these molecules.

Conclusion and Limitations

This research identifies specific hypomethylated, CpG-rich cfDNA sequences as primary drivers of joint inflammation in RA. These molecules serve as both potential biomarkers for diagnosis and novel targets for therapeutic intervention. However, the study notes that it remains unclear why these particular sequences are hypomethylated. Future research may explore restoring DNase activity or using molecular scavengers to neutralize these inflammatogenic molecules before they trigger clinical flares.

Summary updated

Abstract

Elevated cell-free DNA (cfDNA) levels in the plasma and synovial fluid of rheumatoid arthritis (RA) patients are proposed to be pathologically relevant. However, direct evidence to support this perception is lacking, and molecular feature of the cfDNA molecules with assumed pathological function is not well characterized. Here, we confirm remarkably increased levels of total synovial fluid and plasma cfDNAs in a large cohort of patients with rheumatoid arthritis compared to the counterparts in osteoarthritis, and demonstrate the potent inflammatogenic effects of RA synovial fluid cfDNA on both human monocyte cell line and primary cells related to RA. Massively parallel sequencing identifies distinct molecular pattern of cfDNA in RA, as characterized by enriching CpG-motif containing sequences. Importantly, these identified CpG-motif-rich sequences are hypomethylated in RA patients and induce severe inflammatory responses both <i>in vitro</i> and <i>in vivo</i>. Our data demonstrate the pathological role of global and specific cfDNA molecules in RA, thereby identifying novel therapeutic target candidate and potential biomarker for RA.
BibTeX
@inproceedings{dong2020identification,
  author = {Cong Dong and Yu Liu and Chengxin Sun and Huiyi Liang and Lie Dai and Jun Shen and Wei Song and Shixin Guo and Kam W. Leong and Yongming Chen and Lai Wei and Lixin Liu},
  title = {{Identification of Specific Joint-Inflammatogenic Cell-Free DNA Molecules From Synovial Fluids of Patients With Rheumatoid Arthritis}},
  booktitle = {Frontiers in Immunology},
  year = {2020},
  doi = {10.3389/fimmu.2020.00662},
}
Figure